Naslov
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

Autori
Mocroft, Amanda ; Miro, Jose M. ; Wandeler, Gilles ; Llibre, Josep M. ; Boyd, Anders ; van Bremen, Kathrin ; Beniowski, Marek ; Mikhalik, Julia ; Cavassini, Matthias ; Maltez, Fernando ; Duvivier, Claudine ; Uberti Foppa, Caterina ; Knysz, Brygida ; Bakowska, Elzbieta ; Kuzovatova, Elena ; Domingo, Pere ; Zagalo, Alexandra ; Viard, Jean‐ Paul ; Degen, Olaf ; Milinković, Ana ; Benfield, Thomas ; Peters, Lars ; Begovac, Josip

Kolaboracija
EuroSIDA study group

Izvornik
Hiv medicine (1464-2662) 23 (2021), 6; 585-598

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
HBV DNA ; hepatitis B ; nonliver cancer

Sažetak
Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study ; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU ; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU ; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV- negative individuals [adjusted incidence rate ratio (aIRR) 1.23 ; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA- positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37 ; 95% CI 1.00–1.89) and NHL (aIRR 2.57 ; 95% CI 1.16– 5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA